Michael leads Chemistry and Drug Discovery at Dewpoint Therapeutics. He has over 20 years of drug discovery and chemistry experience at Sanofi. Before joining Dewpoint, Michael helped to build several early-stage biotech companies in the field of drug discovery, biomolecular imaging, and drug delivery.
Previously, Michael led the Synthetic Medicinal Modalities Department at Sanofi, where he was responsible for the Frankfurt small molecule portfolio, peptide drug discovery, synthetic proteins and conjugates, as well as new delivery technologies for sustained, oral and smart delivery of biomolecules.
During his 20-year career in the pharmaceutical industry, in positions with increasing responsibility, Michael has built a successful track record of building and leading functional groups to drive drug discovery and delivering high quality candidates for clinical development comprising different therapeutic modalities in multiple therapeutic areas, including cardiovascular disease, metabolic disease, pain, immunology and rare disease. His direct scientific contributions have resulted in more than 15 clinical development candidates and more than 80 patents and peer-reviewed publications.
Michael has served on numerous scientific advisory boards and is active in various professional societies for the advancement of chemical sciences and peptide sciences. Michael holds a PhD in organic and bioorganic chemistry from the University of Mainz, Germany.